SIGLEC1 and metastatic prostate carcinoma: Strömvall et al. [9] showed that CD169 expression was decreased in pre-metastatic LNs in a rat metastatic prostate cancer model, and that reduced CD169 expression in LSMs was associated with worse cancer-specific survival in human prostate cancer.